Compatibility of Dupilumab-like formulation in 2.25 mL autoinjector paired with prefillable syringes under accelerated aging conditions

October 07 2026

Summary

System-level compatibility between the primary container and autoinjector is an important consideration in combination product development, particularly when formulation characteristics and primary-container materials may influence performance over time. This poster evaluates the performance of the Molly 2.25 mL autoinjector platform in combination with two types of silicone-coated prefillable syringes containing a high-polysorbate, Dupilumab-like formulation. Following accelerated aging designed to simulate up to two years of shelf life, the system maintained consistent injection times, dose delivery, needle extension, cap-removal force, and activation force across the tested syringe types and aging conditions.

 

Key takeaways

  • The Molly 2.25 mL autoinjector maintained consistent performance across both syringe siliconization types (Alba prefilled syringe with crosslinked silicone and Nexa prefilled syringe with optimized silicone-oil) and all three evaluated time points, which includes six months of accelerated aging designed to simulate two years of shelf life.
  • For both syringe types, all measured delivered doses remained above the minimum required dose across all three time points.
  • The findings reinforce the importance of evaluating the primary container and autoinjector as an integrated system, rather than relying solely on component-level characterization, when assessing compatibility and mitigating development risk.

 

Document details 

  • Format: Scientific poster 
  • Authors:

Dr. Nina Fetz, Senior Manager Customer Solutions, SHL Medical

Enrico Barichello, Product Manager, Syringe Platform, Stevanato Group 

  • Speaker: Alan Xu, Product Manager, Drug Containment Solutions, Stevanato Group
  • Page count: 1 page 
  • Estimated read time: 5-10 minutes
[.jpg] SHL Medical x SG - Molly PDA Universe 2026 Poster Preview Image